CagriSema: A Tracking Guide for a Cagrilintide and Semaglutide Combination

CagriSema is a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a GLP-1 receptor agonist, developed by Novo Nordisk as a once-weekly injection. The two mechanisms stack: GLP-1 blunts appetite and slows gastric emptying, while amylin adds its own satiety signaling. In the REDEFINE program, CagriSema produced roughly 22.7 percent mean weight loss at 68 weeks, versus about 16.0 percent for semaglutide alone and 1.8 percent for placebo.

Importantly, CagriSema is not approved. Novo Nordisk filed an FDA application in December 2025, with a decision expected around late 2026. This is an educational tracking guide about an investigational combination, not medical advice or a recommendation.

What it does

• Combines amylin and GLP-1 agonism for stronger appetite suppression than either alone
• Slows gastric emptying and increases satiety
• Drives fat loss in trials that exceeds semaglutide monotherapy

Typical protocol shape

In the trials, CagriSema is titrated upward over weeks toward the combined maintenance dose to limit gastrointestinal side effects, and given as a once-weekly subcutaneous injection. Any dose numbers here reflect the trial program only, not a personal recommendation.

What to track daily

• Appetite, portion sizes, and early fullness
• Nausea, vomiting, diarrhea, or constipation
• Resting heart rate

What to track weekly

• Bodyweight under consistent conditions
• Waist circumference
• Injection-site tolerance, including redness, lumps, or soreness
• Grip strength or a simple lift to watch for muscle loss during rapid weight loss

Bloodwork worth doing

• Fasting glucose and HbA1c
• Lipid panel over time
• Note any personal or family history of medullary thyroid carcinoma, a class contraindication

Realistic expectations

The strong trial numbers reflect controlled conditions with titration and support. Weight loss is gradual, and a meaningful share during rapid loss can be lean mass, so protein intake and resistance training deserve dedicated tracking alongside the scale and waist.

Common mistakes

• Treating an unapproved combination as if it were a settled therapy
• Ignoring protein and strength work and losing muscle
• Dismissing persistent GI symptoms or dehydration

Safety notes

CagriSema is investigational and not FDA approved as of mid-2026. Based on its components, expect the GLP-1 class boxed warning for thyroid C-cell tumors and contraindications in medullary thyroid carcinoma or MEN 2, plus nausea, vomiting, diarrhea, and risks of pancreatitis, gallbladder disease, and dehydration. Anyone accessing it outside a trial is outside the evidence base and should be under medical supervision.

Peptid AI is an educational and self-tracking tool. Nothing in this post is medical advice. Doses mentioned reflect what is commonly reported in research literature — they are not recommendations. Always consult a qualified physician before starting, changing, or stopping any protocol.